SYRE
$41.25-1.06 (-2.51%)
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
Recent News
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns
Why Spyre Therapeutics Stock Is On Investors’ Radar Spyre Therapeutics (SYRE) has attracted attention after a strong share price move over the past year, alongside meaningful swings in shorter term returns that may prompt investors to reassess risk and reward. See our latest analysis for Spyre Therapeutics. Recent trading has been choppy, with a 2.32% 1 day share price return and a 6.56% 7 day share price decline. However, a 25.19% 30 day share price return and a 110.58% 1 year total...
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.